Long-Term Correction of Murine Lipoprotein Lipase Deficiency with AAV1-Mediated Gene Transfer of the Naturally Occurring LPL S447X Beneficial Mutation
The DOI matches its OpenAlex record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Human lipoprotein lipase (LPL) deficiency causes profound hypertriglyceridemia and life-threatening pancreatitis. We recently developed an adult murine model for LPL deficiency: LPL -/- mice display grossly elevated plasma triglyceride (TG) levels (>200-fold) and very low high-density lipoprotein cholesterol (HDL-C < 10% of normal). We used this animal model to test the efficacy of adeno-associated virus-mediated expression of hLPL(S447X) (AAV1-LPL(S447X)) in muscle for the treatment of LPL deficiency. Intramuscular administration of AAV1-LPL(S447X) resulted in dose-dependent expression of hLPL protein and LPL activity (up to 33% of normal murine levels) in postheparin plasma. Remarkably, visible hyperlipidemia was resolved within 1 week; plasma TG was reduced to near-normal levels (from 99.0 to 1.8 mmol/L), and plasma HDL-C was increased 6-fold (from 0.2 to 1.1 mmol/L). At 8 months after administration of AAV1-LPL(S447X), an intravenous lipid challenge showed efficient, near-normal clearance of plasma TG. Histologic analyses of injected muscle further indicated that abnormal muscle morphology observed in LPL -/- mice was reversed after treatment. Expression of therapeutic levels of LPL(S447X), and the subsequent beneficial effect on plasma lipid levels, has lasted for more than 1 year. We therefore conclude that AAV1-mediated transfer of LPL(S447X) into murine skeletal muscle results in long-term near-correction of dyslipidemia associated with LPL deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Gene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541 · cited 1×
“Most widely used is AAV serotype 2 (AAV2); however, several groups have demonstrated that AAV1, AAV5, and AAV7 transduce muscle cells more efficiently (Xiao et al ., 1999; Chao et al ., 2000, 2001; Arruda et al ., 2004).”
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0219 · Cited by 366
Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element
Donello, J. E., Loeb, J. E., & Hope, T. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.5085-5092.1998 · Cited by 350 · cited 1×
“The bovine growth hormone polyadenylation sequence (bGH polyA) and woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) were added to enhance transcription (Donello et al ., 1998).”
Grimm, D., Kay, M. A., & Kleinschmidt, J. A. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00095-9 · Cited by 344 · cited 1×
“rAAV vectors were produced by calcium phosphate-medi-ated cotransfection of AAV1 helper plasmid pDP1, a derivative of pDG (Grimm et al ., 2003) and vector plasmid (pVD5 or pTRCGW) in 293 cells (Hermens et al ., 1999). pDP1 was used to produce recombinant (r)AAV with AAV2 inverted terminal repeats…”
Wittrup, H. H., Tybjærg-Hansen, A., & Nordestgaard, B. G. (1999) · Circulation · doi:10.1161/01.cir.99.22.2901 · Cited by 344 · cited 1×
“…mutation that is associated with significant benefits, including decreased plasma TG and increased high-density lipoprotein cholesterol (HDL-C; Groenemeijer et al ., 1997; Kuivenhoven et al ., 1997; Wittrup et al ., 1999; Garenc et al ., 2000; Chen et al ., 2001; Clee et al ., 2001).”
Herzog, R. W., Mount, J. D., Arruda, V. R., High, K. A., & Lothrop, C. D. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0442 · Cited by 176
Cited by
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Self-citationChang, B. H.-J., Li, L., Paul, A., Taniguchi, S., Nannegari, V., Heird, W. C., & Chan, L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.3.1063-1076.2006 · Cited by 309
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Self-citationLessons learned from the clinical development and market authorization of Glybera
Bryant, L. M., Christopher, D. M., Giles, A. R., Hinderer, C., Rodriguez, J. L., Smith, J. B., Traxler, E. A., Tycko, J., Wojno, A. P., & Wilson, J. M. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.087 · Cited by 189
“The recombinant vector used for this study, AAV1-LPLS447X, was produced in this way, using Cap proteins from AAV serotype 1 and ITRs from AAV2 (Rip et al., 2005).”
MethodInfluentialGene therapy for lipoprotein lipase deficiency
Gaudet, D., Méthot, J., & Kastelein, J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283555a7e · Cited by 178
Self-citation
Metadata
- Authors
- Ross, C. J., Twisk, J., Meulenberg, J. J. M., Liu, G., van den Oever, K., Moraal, E., Hermens, W. T., Rip, J., Kastelein, J. J. P., Kuivenhoven, J. A., & Hayden, M. R.
- Venue
- Human Gene Therapy
- Publisher
- Mary Ann Liebert, Inc.
- Published
- 2004-09-01
- Volume
- 15
- Issue
- 9
- Pages
- 906-919
- ISSN
- 1043-0342 (ISSN-L)
- OpenAlex
- W2120322365
- Cited by
- 80
- References
- 7
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Correction of Murine Lipoprotein Lipase Deficiency with AAV1-Mediated Gene Transfer of the Naturally Occurring LPL S447X Beneficial Mutation. https://app.cochat.ai/papers/10.1089/1043034041839235
- The paper
- Ross, C. J., Twisk, J., Meulenberg, J. J. M., Liu, G., van den Oever, K., Moraal, E., Hermens, W. T., Rip, J., Kastelein, J. J. P., Kuivenhoven, J. A., & Hayden, M. R. (2004). Long-Term Correction of Murine Lipoprotein Lipase Deficiency with AAV1-Mediated Gene Transfer of the Naturally Occurring LPL S447X Beneficial Mutation. Human Gene Therapy. https://doi.org/10.1089/1043034041839235
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.